Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Other ICR Research
  • View item
  • Home
  • ICR Divisions
  • Other ICR Research
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Investigation of the incidence of "undesirable" molecular moieties for high-throughput screening compound libraries in marketed drug compounds

Thumbnail
Date
2009
ICR Author
Axerio-Cilies, Peter
Castaneda, Ivan
Type
Journal Article
Metadata
Show full item record
Abstract
A database of 1070 marketed drug compounds was compiled and analyzed in order to assess the occurrence of moieties described in the literature as "undesirable" for high-throughput screening compound libraries due to their ability to perturb assay formats. The study revealed a total of 277 compounds, 26% of the database, contained at least one of the moieties. As some of the drug compounds contained more than one "undesirable" moiety, the total number was 352. Electrophilic reactive groups, particularly aliphatic esters, were the most abundant type with 55% of the total. Half of the drug compounds incorporating the "undesirable" moieties were synthetic organic molecules. These findings suggest that "undesirable" moieties do not pose a major hindrance during clinical trials, the most expensive phase of drug development. In addition, their early elimination in the preclinical. stage excludes large regions of known drug space due to the reliance on biochemical and cell-based assays. In general, it can be concluded that compounds with "undesirable" moieties should not simply be eliminated from compound screening libraries but rather be flagged as potentially problematic. A possible solution is to segregate the compounds containing suspect moieties and screen them when deemed appropriate. (C) 2008 Elsevier Masson SAS. All rights reserved.
URI
https://repository.icr.ac.uk/handle/internal/1960
Collections
  • Other ICR Research
Subject
Drug chemical space Toxic and promiscuous chemical moieties Drug- and lead-like chemical space and drug discovery PROMISCUOUS INHIBITORS PROPERTY PROFILES ORAL-DRUGS DISCOVERY PERMEABILITY SOLUBILITY MECHANISM HTS DNA
Language
eng
License start date
2009
Citation
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2009, 44 (3), pp. 1128 - 1134

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.